alexa Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.


Journal of Kidney

Author(s): Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME,

Abstract Share this page

Abstract BACKGROUND: Patients with end-stage renal disease (ESRD) receiving dialysis have been reported to have increased risk of cancer. However, contemporary cancer burden estimates in this population are sparse and do not account for the high competing risk of death characteristic of dialysis patients. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: US adult patients enrolled in Medicare's ESRD program who received in-center hemodialysis. FACTORS: Demographic/clinical characteristics. OUTCOMES: For overall and site-specific cancers identified using claims-based definitions, we calculated annual incidence rates (1996-2009). We estimated 5-year cumulative incidence since dialysis therapy initiation using competing-risk methods. RESULTS: We observed a constant rate of incident cancers for all sites combined, from 3,923 to 3,860 cases per 100,000 person-years (annual percentage change, 0.1; 95\% CI, -0.4 to 0.6). Rates for some common site-specific cancers increased (ie, kidney/renal pelvis) and decreased (ie, colon/rectum, lung/bronchus, pancreas, and other sites). Of 482,510 incident hemodialysis patients, cancer was diagnosed in 37,128 within 5 years after dialysis therapy initiation. The 5-year cumulative incidence of any cancer was 9.48\% (95\% CI, 9.39\%-9.57\%) and was higher for certain subgroups: older age, males, nonwhites, non-Hispanics, nondiabetes primary ESRD cause, recent dialysis therapy initiation, and history of transplantation evaluation. Among blacks and whites, we observed 35,767 cases compared with 25,194 expected cases if the study population had experienced rates observed in the US general population (standardized incidence ratio [SIR], 1.42; 95\% CI, 1.41-1.43). Risk was most elevated for cancers of the kidney/renal pelvis (SIR, 4.03; 95\% CI, 3.88-4.19) and bladder (SIR, 1.57; 95\% CI, 1.51-1.64). LIMITATIONS: Claims-based cancer definitions have not been validated in the ESRD population. Information for cancer risk factors was not available in our data source. CONCLUSIONS: These results suggest a high burden of cancer in the dialysis population compared to the US general population, with varying patterns of cancer incidence in subgroups. Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
This article was published in Am J Kidney Dis and referenced in Journal of Kidney

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 2nd Annual Kidney Congress
    Aug 28-30, 2017, Philadelphia, USA
  • 16th European Nephrology Conference
    Oct 02-04, 2017, Barcelona, Spain
  • 16th International Conference on Nephrology
    Nov 02-03, 2017, Atlanta, USA

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version